Machine perfusion of explanted organs is an
interesting and novel method to repair injured organs before implantation. 2. Different technologies need to be compared in the future. Combined approaches (hypothermic/subnormothermic 1 normothermic) appear highly attractive to reduce reperfusion injury and to assess graft quality.
Liver transplantation is an overall success story and has led worldwide to many more candidates on waiting lists than donor organs available. (1, 2) This discrepancy between liver supply and demand has forced professionals to consider grafts from so-called extended criteria donors. Such livers induce, however, far more posttransplant complications, including primary nonfunction, early allograft dysfunction, biliary complications, and graft loss. (3) (4) (5) Key factors for liver graft dysfunction include donor warm ischemia (donation after circulatory death [DCD]), graft steatosis, and prolonged conventional cold storage of more than 10 hours.
(1,2,6) Graft optimization or repair strategies before implantation are therefore of high importance to improve outcome. This presentation will focus on underlying mechanisms of injury throughout procurement and implantation with a special emphasis on hypothermic machine perfusion (HMP).
Injury During Procurement and Implantation
Liver injury already starts before organ procurement, eg, during donation after brain death (DBD) or due to donor warm ischemia in DCD. After such initial injury already in donors, liver grafts undergo the process of retrieval surgery, including a cold flush and cold storage. Although cooling is a well-established procedure to slow down energy demand, a number of negative effects have been reported, eg, depletion of adenine nucleotide pool, (7) lactate acidosis, (8) increase of chelatable iron, (9) intracellular calcium accumulation, (10) calpain activation, (11, 12) and sinusoidal endothelial damage. (13) All these effects are triggered by anaerobic metabolism and therefore limit the maximum time period for cold storage due to deleterious effects on plasma membrane lipids, cytoskeleton, microtubules, and mitochondria, disabling the ion-exchange pumps and consequent membrane swelling and cell lysis. (14) During implantation, liver grafts are further exposed to ischemic rewarming, once more aggravating anaerobic metabolism. Subsequently, a re-exposure with normothermic blood and oxygen during implantation triggers an immediate burst of reactive oxygen species (ROS) within the first minutes of reperfusion. (15) The mechanism behind this has been shown to be dependent on mitochondrial-derived injury, (16) caused by mitochondrial electron leaks, mainly due to reverse electron flow from mitochondrial complex II to complex I. (17) This correlates with massive oxidative injury of mitochondrial membranes and also DNA, (18) and it results in downstream release of danger-associated molecular patterns (DAMPs), (19) activating of toll-like receptors located on nonparenchymal liver cells, and in the release of numerous inflammatory mediators (Fig. 1) . (20) Any efforts to restore blood flow in hypoxic tissue, therefore, paradoxically induce potentially more destructive than beneficial effects, depending on the amount of accumulated injury during the ischemic period. (21) Abbreviations: ADP, adenosine diphosphate; ATP, adenosine triphosphate; DAMP, danger-associated molecular pattern; DBD, donation after brain death; DCD, donation after circulatory death; HMP, hypothermic machine perfusion; FAD, flavin adenine dinucleotide; FADH2, flavine adenine dinucleotide hydroxide; HOPE, hypothermic oxygenated perfusion; NADH, reduced nicotinamide adenine dinucleotide; ROS, reactive oxygen species.
Hypothermic Perfusion Concept

IDEA AND MECHANISM
The current data point to the fact that oxygenation of the mitochondrial electron chain under hypothermic conditions, eg, hypothermic oxygenated perfusion (HOPE), is the key element for the protection of HMP against reperfusion injury. (22) Three effects emerge due to HOPE. First, function of mitochondrial enzyme complexes is improved during cold oxygenated perfusion, probably leading to forward instead of reverse electron flow. Second, adenine nucleotides are significantly uploaded to high levels during cold oxygenation, consecutively to a "repair" of mitochondrial function. (23) Third, the cellular redox state changes from reduced to oxidized. (23) Treatment by HOPE results therefore in less oxidative injury, less release of DAMPs, less activation of toll-like receptors, and improved liver function upon implantation. This effect is similar for DCD and steatotic liver grafts. (24, 25) Furthermore, HOPE is not only effective against reperfusion injury but prevents also downstream activation of immune response pathways. (26) One of the major advantages of HMP is its easy applicability, eg, an end-ischemic approach after initial cold storage is effective. Thus, machine perfusion under cold conditions does not necessarily need to start at the place of organ donation. (25) Furthermore, HOPE perfusion was equally protective in DCD kidneys in a rodent model of kidney transplantation. (27) CLINICAL DATA Hypothermic dual (portal vein and hepatic artery) perfusion of the first 20 standard DBD human livers was reported in 2010 by Guarerra et al. (28) Machine perfusion was applied without additional active oxygenation after previous cold storage and transport of organs to the perfusion center. Notably, despite the lack of oxygenators in the circuit, the perfusate partial pressure of oxygen was sufficient in enabling aerobic conditions during perfusion. (28) The results showed that perfusion resulted in significantly less peak enzyme release and shorter hospital stay, as well as less early graft dysfunction compared with a nonrandomized control group. (28) In a further report, the same investigators recently showed less biliary complication after application of hypothermic perfusion to marginal DBD organs. (29) Consistent with these results, hypothermic perfusion including active oxygenation (HOPE) has been shown by our group to be protective in human extended DCD liver grafts, despite very long donor warm ischemia times, (30) with no occurrence of intrahepatic biliary complications in contrast to matched unperfused DCD livers. (31) Importantly, HOPE treatment appeared sufficient by single portal vein perfusion because the entire intrahepatic and extrahepatic biliary system is positively affected through multiple collaterals between the portal vein and hepatic artery. (32, 33) Randomized trials are therefore initiated to further evaluate the effect of HOPE on DBD and DCD liver grafts. (34, 35) Notably, a HOPE approach was tested recently in Maastricht Type II DCD livers following normothermic regional perfusion, or after extended cold storage. (36) In addition, the first longterm outcome analysis of HOPE-treated DCD livers has been completed, showing excellent 5-year graft survival comparable with DBD liver transplantations. (37) 
VIABILITY ASSESSMENT
Similarly, to liver enzyme measurements during normothermic perfusion, detection of several parameters during HMP and HOPE is currently under evaluation, eg, microRNA, (38) DAMP release, (39) citric acid metabolites, (40) parameters of mitochondrial function, (41) and nucleotide pool assessment. (42) Several of these compounds may correlate to liver function after transplantation but remain to be further investigated.
FUTURE ASPECTS
Hypothermic perfusion is currently applied endischemically, after initial cold flush and storage. Whether liver grafts can be again cold-stored after short-term HOPE treatment is currently under investigation. Graft optimization in perfusion centers, with afterward cold storage transport to implantation centers, could help to provide more livers for more transplant centers that do not have access to machine perfusion yet.
Conclusion
Repair of injured liver grafts and prediction of organ function before implantation are the 2 major concerns to allow the safe use of organs that were previously regarded as unsuitable. Much effort should therefore be directed to further developments of dynamic preservation methods, which will likewise replace static cold storage in high-risk grafts. In this context, reliable thresholds need to be defined for the difficult decision-which graft will benefit from machine perfusion treatment to provide a lifesaving, but also affordable optimization. More research and international concepts are necessary to further improve ex vivo medical treatment before transplantation, for example, by new perfusion devices, eg, Transmedics machine for normothermic perfusion, or Airdrive for hypothermic perfusion, (43) which will be compared with existing techniques. Highly attractive, however, are relative short perfusion and center-bound treatments of liver grafts before implantation, which can provide significant uploads in cellular energy stores. In all perfusion technologies, modern analytical technologies (eg, proteomics, metabolomics) will be tested on liver tissue and perfusate, and they may help to search for new biomarkers assessing graft quality before implantation. 
